Proarrhythmic activity of intracoronary endothelin in dogs: Relation to the site of administration and to changes in regional flow

P. Salvati, S. Chierchia, L. Dho, R. G. Ferrario, P. Parenti, G. Vicedomini, C. Patrono

Research output: Contribution to journalArticle

Abstract

The endothelium-derived peptid, endothelin, has been shown to exert powerful constrictor activity in both isolated and in situ coronary arteries. Recent in vitro data on isolated cardiac myocytes suggest that the substance might also possess electrophysiologic properties. We investigated the possibility that endothelin (ET-1) may exert proarrhythmic effects when infused selectively in the coronary circulation of open-chest-anesthetized dogs. Animals were instrumented for the measurement of left anterior descending (LAD) or left circumflex (LCX) coronary artery blood flow, left systolic ventricular pressure (LSVP), dPldtmax, mean arterial pressure (MAP), and epicardial electrocardiogram (ECG; three leads). Data were recorded during infusion (2 min) of saline (n = 5) or increasing doses of endothelin (5-80 pmol/kg) given selectively in either the LCX (n = 10) or the LAD (n = 10) When infused into the LCX, endothelin produced a dose-dependent decrease in flow (40 ± 23% at 80 pmol/kg, mean ± SD, p <0.01) with a concomitant increase in coronary resistance and a decrease in dP/dtmax and MAP. ECG changes typical of myocardial ischemia paralleled the decrease in flow and culminated in ventricular sibrillation at the highest dose (80% of dogs). Endothelin caused similar hemodynamic effects when infused in the LAD, but fatal arrhythmias occurred for lower doses and for little or no change in coronary blood flow. Thirty percent of the animals died at 10 and 60% died at 20 pmol/kg, doses that induced only a moderate decrease (8 ± 7 and 21 ± 12%, respectively) in LAD total blood flow. Ventricular tachycardia always preceded ventricular fibrillation and death. In contrast, at equivalent doses, no deaths occurred when endothelin was given in the LCX. even though the decrease in flow was comparable. These results confirm that endothelin is a potent constrictor of dog coronary arteries: they indicate that the compound also exhibits proarrhythmic effects that are not entirely accounted for by ischemia. This effect might be due to a direct activity on cardiac myocytes, particularly pronounced in the LAD district.

Original languageEnglish
Pages (from-to)1007-1014
Number of pages8
JournalJournal of Cardiovascular Pharmacology
Volume17
Issue number6
Publication statusPublished - 1991

Fingerprint

Endothelins
Dogs
Coronary Vessels
Electrocardiography
Cardiac Myocytes
Arterial Pressure
Coronary Circulation
Endothelin-1
Ventricular Fibrillation
Ventricular Pressure
Ventricular Tachycardia
Endothelium
Myocardial Ischemia
Cardiac Arrhythmias
Thorax
Ischemia
Hemodynamics
Blood Pressure

Keywords

  • Coronary circulation
  • Isolated resistance arteries
  • Lethal arrhythmias
  • Myocardial ischemia

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

Salvati, P., Chierchia, S., Dho, L., Ferrario, R. G., Parenti, P., Vicedomini, G., & Patrono, C. (1991). Proarrhythmic activity of intracoronary endothelin in dogs: Relation to the site of administration and to changes in regional flow. Journal of Cardiovascular Pharmacology, 17(6), 1007-1014.

Proarrhythmic activity of intracoronary endothelin in dogs : Relation to the site of administration and to changes in regional flow. / Salvati, P.; Chierchia, S.; Dho, L.; Ferrario, R. G.; Parenti, P.; Vicedomini, G.; Patrono, C.

In: Journal of Cardiovascular Pharmacology, Vol. 17, No. 6, 1991, p. 1007-1014.

Research output: Contribution to journalArticle

Salvati, P, Chierchia, S, Dho, L, Ferrario, RG, Parenti, P, Vicedomini, G & Patrono, C 1991, 'Proarrhythmic activity of intracoronary endothelin in dogs: Relation to the site of administration and to changes in regional flow', Journal of Cardiovascular Pharmacology, vol. 17, no. 6, pp. 1007-1014.
Salvati, P. ; Chierchia, S. ; Dho, L. ; Ferrario, R. G. ; Parenti, P. ; Vicedomini, G. ; Patrono, C. / Proarrhythmic activity of intracoronary endothelin in dogs : Relation to the site of administration and to changes in regional flow. In: Journal of Cardiovascular Pharmacology. 1991 ; Vol. 17, No. 6. pp. 1007-1014.
@article{d1ad90566e1c485bb7aa27f5f56fd77e,
title = "Proarrhythmic activity of intracoronary endothelin in dogs: Relation to the site of administration and to changes in regional flow",
abstract = "The endothelium-derived peptid, endothelin, has been shown to exert powerful constrictor activity in both isolated and in situ coronary arteries. Recent in vitro data on isolated cardiac myocytes suggest that the substance might also possess electrophysiologic properties. We investigated the possibility that endothelin (ET-1) may exert proarrhythmic effects when infused selectively in the coronary circulation of open-chest-anesthetized dogs. Animals were instrumented for the measurement of left anterior descending (LAD) or left circumflex (LCX) coronary artery blood flow, left systolic ventricular pressure (LSVP), dPldtmax, mean arterial pressure (MAP), and epicardial electrocardiogram (ECG; three leads). Data were recorded during infusion (2 min) of saline (n = 5) or increasing doses of endothelin (5-80 pmol/kg) given selectively in either the LCX (n = 10) or the LAD (n = 10) When infused into the LCX, endothelin produced a dose-dependent decrease in flow (40 ± 23{\%} at 80 pmol/kg, mean ± SD, p <0.01) with a concomitant increase in coronary resistance and a decrease in dP/dtmax and MAP. ECG changes typical of myocardial ischemia paralleled the decrease in flow and culminated in ventricular sibrillation at the highest dose (80{\%} of dogs). Endothelin caused similar hemodynamic effects when infused in the LAD, but fatal arrhythmias occurred for lower doses and for little or no change in coronary blood flow. Thirty percent of the animals died at 10 and 60{\%} died at 20 pmol/kg, doses that induced only a moderate decrease (8 ± 7 and 21 ± 12{\%}, respectively) in LAD total blood flow. Ventricular tachycardia always preceded ventricular fibrillation and death. In contrast, at equivalent doses, no deaths occurred when endothelin was given in the LCX. even though the decrease in flow was comparable. These results confirm that endothelin is a potent constrictor of dog coronary arteries: they indicate that the compound also exhibits proarrhythmic effects that are not entirely accounted for by ischemia. This effect might be due to a direct activity on cardiac myocytes, particularly pronounced in the LAD district.",
keywords = "Coronary circulation, Isolated resistance arteries, Lethal arrhythmias, Myocardial ischemia",
author = "P. Salvati and S. Chierchia and L. Dho and Ferrario, {R. G.} and P. Parenti and G. Vicedomini and C. Patrono",
year = "1991",
language = "English",
volume = "17",
pages = "1007--1014",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Proarrhythmic activity of intracoronary endothelin in dogs

T2 - Relation to the site of administration and to changes in regional flow

AU - Salvati, P.

AU - Chierchia, S.

AU - Dho, L.

AU - Ferrario, R. G.

AU - Parenti, P.

AU - Vicedomini, G.

AU - Patrono, C.

PY - 1991

Y1 - 1991

N2 - The endothelium-derived peptid, endothelin, has been shown to exert powerful constrictor activity in both isolated and in situ coronary arteries. Recent in vitro data on isolated cardiac myocytes suggest that the substance might also possess electrophysiologic properties. We investigated the possibility that endothelin (ET-1) may exert proarrhythmic effects when infused selectively in the coronary circulation of open-chest-anesthetized dogs. Animals were instrumented for the measurement of left anterior descending (LAD) or left circumflex (LCX) coronary artery blood flow, left systolic ventricular pressure (LSVP), dPldtmax, mean arterial pressure (MAP), and epicardial electrocardiogram (ECG; three leads). Data were recorded during infusion (2 min) of saline (n = 5) or increasing doses of endothelin (5-80 pmol/kg) given selectively in either the LCX (n = 10) or the LAD (n = 10) When infused into the LCX, endothelin produced a dose-dependent decrease in flow (40 ± 23% at 80 pmol/kg, mean ± SD, p <0.01) with a concomitant increase in coronary resistance and a decrease in dP/dtmax and MAP. ECG changes typical of myocardial ischemia paralleled the decrease in flow and culminated in ventricular sibrillation at the highest dose (80% of dogs). Endothelin caused similar hemodynamic effects when infused in the LAD, but fatal arrhythmias occurred for lower doses and for little or no change in coronary blood flow. Thirty percent of the animals died at 10 and 60% died at 20 pmol/kg, doses that induced only a moderate decrease (8 ± 7 and 21 ± 12%, respectively) in LAD total blood flow. Ventricular tachycardia always preceded ventricular fibrillation and death. In contrast, at equivalent doses, no deaths occurred when endothelin was given in the LCX. even though the decrease in flow was comparable. These results confirm that endothelin is a potent constrictor of dog coronary arteries: they indicate that the compound also exhibits proarrhythmic effects that are not entirely accounted for by ischemia. This effect might be due to a direct activity on cardiac myocytes, particularly pronounced in the LAD district.

AB - The endothelium-derived peptid, endothelin, has been shown to exert powerful constrictor activity in both isolated and in situ coronary arteries. Recent in vitro data on isolated cardiac myocytes suggest that the substance might also possess electrophysiologic properties. We investigated the possibility that endothelin (ET-1) may exert proarrhythmic effects when infused selectively in the coronary circulation of open-chest-anesthetized dogs. Animals were instrumented for the measurement of left anterior descending (LAD) or left circumflex (LCX) coronary artery blood flow, left systolic ventricular pressure (LSVP), dPldtmax, mean arterial pressure (MAP), and epicardial electrocardiogram (ECG; three leads). Data were recorded during infusion (2 min) of saline (n = 5) or increasing doses of endothelin (5-80 pmol/kg) given selectively in either the LCX (n = 10) or the LAD (n = 10) When infused into the LCX, endothelin produced a dose-dependent decrease in flow (40 ± 23% at 80 pmol/kg, mean ± SD, p <0.01) with a concomitant increase in coronary resistance and a decrease in dP/dtmax and MAP. ECG changes typical of myocardial ischemia paralleled the decrease in flow and culminated in ventricular sibrillation at the highest dose (80% of dogs). Endothelin caused similar hemodynamic effects when infused in the LAD, but fatal arrhythmias occurred for lower doses and for little or no change in coronary blood flow. Thirty percent of the animals died at 10 and 60% died at 20 pmol/kg, doses that induced only a moderate decrease (8 ± 7 and 21 ± 12%, respectively) in LAD total blood flow. Ventricular tachycardia always preceded ventricular fibrillation and death. In contrast, at equivalent doses, no deaths occurred when endothelin was given in the LCX. even though the decrease in flow was comparable. These results confirm that endothelin is a potent constrictor of dog coronary arteries: they indicate that the compound also exhibits proarrhythmic effects that are not entirely accounted for by ischemia. This effect might be due to a direct activity on cardiac myocytes, particularly pronounced in the LAD district.

KW - Coronary circulation

KW - Isolated resistance arteries

KW - Lethal arrhythmias

KW - Myocardial ischemia

UR - http://www.scopus.com/inward/record.url?scp=0026003080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026003080&partnerID=8YFLogxK

M3 - Article

C2 - 1714004

AN - SCOPUS:0026003080

VL - 17

SP - 1007

EP - 1014

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 6

ER -